These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 12379620)

  • 1. Treatments no longer in development for rheumatoid arthritis.
    Keystone E
    Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii43-5. PubMed ID: 12379620
    [No Abstract]   [Full Text] [Related]  

  • 2. [New treatments for rheumatoid arthritis].
    Girault V; Flipo RM
    Soins; 2004 Sep; (688):37-8. PubMed ID: 15515847
    [No Abstract]   [Full Text] [Related]  

  • 3. Treating rheumatoid arthritis with tumour necrosis factor alpha blockade.
    Emery P; Buch M
    BMJ; 2002 Feb; 324(7333):312-3. PubMed ID: 11834544
    [No Abstract]   [Full Text] [Related]  

  • 4. When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?
    Smolen JS; Weinblatt ME
    Ann Rheum Dis; 2008 Nov; 67(11):1497-8. PubMed ID: 18854512
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Roos JC; Ostor AJ
    N Engl J Med; 2006 Nov; 355(19):2046-7; author reply 2048. PubMed ID: 17093259
    [No Abstract]   [Full Text] [Related]  

  • 6. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment.
    Harriman G; Harper LK; Schaible TF
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I61-4. PubMed ID: 10577975
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of blockade of tumor necrosis factor alpha on VLA-1+ T-cells in rheumatoid arthritis patients.
    Ben-Horin S; Goldstein I; Koltakov A; Langevitz P; Ehrenfeld M; Rosenthal E; Gur H; Bank I
    J Clin Immunol; 2007 Nov; 27(6):580-8. PubMed ID: 17891451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future use of biologic agents alone and in combination for the treatment of rheumatoid arthritis.
    Strand V
    Z Rheumatol; 1998 Feb; 57(1):41-5. PubMed ID: 9566107
    [No Abstract]   [Full Text] [Related]  

  • 9. [Experimental therapy of rheumatoid arthritis with antibodies to tumor necrosis factor].
    Manger B
    Z Rheumatol; 1998 Oct; 57(5):298-301. PubMed ID: 9864834
    [No Abstract]   [Full Text] [Related]  

  • 10. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials.
    Rau R
    Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii70-3. PubMed ID: 12379628
    [No Abstract]   [Full Text] [Related]  

  • 11. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab.
    Gelinck LB; Teng YK; Rimmelzwaan GF; van den Bemt BJ; Kroon FP; van Laar JM
    Ann Rheum Dis; 2007 Oct; 66(10):1402-3. PubMed ID: 17881666
    [No Abstract]   [Full Text] [Related]  

  • 12. [TNF-alpha antibody in rheumatoid arthritis. Efficacy-risk relationship is positively evaluated].
    MMW Fortschr Med; 2002 May; 144(20):65. PubMed ID: 12119893
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.
    Maini RN; Taylor PC; Paleolog E; Charles P; Ballara S; Brennan FM; Feldmann M
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I56-60. PubMed ID: 10577974
    [No Abstract]   [Full Text] [Related]  

  • 14. Infliximab for rheumatoid arthritis in a patient with tuberculosis.
    Matsumoto T; Tanaka T; Kawase I
    N Engl J Med; 2006 Aug; 355(7):740-1. PubMed ID: 16914717
    [No Abstract]   [Full Text] [Related]  

  • 15. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Antoni CE; Bijlsma JW; Burmester GR; Cronstein B; Keystone EC; Kavanaugh A; Klareskog L
    Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii2-7. PubMed ID: 12379612
    [No Abstract]   [Full Text] [Related]  

  • 16. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
    Baslund B; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prospect for cytokine based therapeutic strategies in rheumatoid arthritis.
    Campion GV
    Ann Rheum Dis; 1994 Aug; 53(8):485-7. PubMed ID: 7944630
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pharmacotherapy of rheumatoid arthritis in the era of genetically engineered biological preparations].
    Nasonov EL
    Ter Arkh; 2007; 79(5):5-8. PubMed ID: 17672066
    [No Abstract]   [Full Text] [Related]  

  • 19. [Experimental therapy of rheumatoid arthritis with cytokine antagonists].
    Manger B
    Z Rheumatol; 1995; 54(2):105-9. PubMed ID: 7793156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis.
    Baldwin HM; Ito-Ihara T; Isaacs JD; Hilkens CM
    Ann Rheum Dis; 2010 Jun; 69(6):1200-7. PubMed ID: 19773288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.